Zum Hauptinhalt springen

COMPOUNDS HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY

SAKAGAMI, Masahiro ; Hashizume, Hiroshi ; et al.
2012
Online Patent

Titel:
COMPOUNDS HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY
Autor/in / Beteiligte Person: SAKAGAMI, Masahiro ; Hashizume, Hiroshi ; Tanaka, Satoru
Link:
Veröffentlichung: 2012
Medientyp: Patent
Sonstiges:
  • Nachgewiesen in: USPTO Patent Applications
  • Sprachen: English
  • Document Number: 20120130070
  • Publication Date: May 24, 2012
  • Appl. No: 13/354881
  • Application Filed: January 20, 2012
  • Assignees: Shionogi & Co., Ltd. (Osaka-shi, JP)
  • Claim: 1. A compound of formula (I): [chemical expression included] or a pharmaceutically acceptable salt thereof, wherein: R1 is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, or substituted or unsubstituted alkynyl; R2 is hydrogen or, substituted or unsubstituted alkyl; Ring A is pyrrolopyridine; R3 is substituted or unsubstituted aryl, substituted or unsubstituted h eteroaryl, or substituted or unsubstituted heterocyclyl; R4 is halogen, cyano, nitro, nitroso, azide, oxo, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, hydroxy, substituted or unsubstituted alkoxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted cycloalkyloxy, substituted or unsubstituted cycloalkenyloxy, substituted or unsubstituted aryloxy, substituted or unsubstituted heteroaryloxy, substituted or unsubstituted heterocyclyloxy, mercapto, substituted or unsubstituted alkylthio, substituted or unsubstituted alkenylthio, substituted or unsubstituted cycloalkylthio, substituted or unsubstituted cycloalkenylthio, substituted or unsubstituted arylthio, substituted or unsubstituted heteroarylthio, substituted or unsubstituted heterocyclylthio, carboxy, substituted or unsubstituted alkoxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted cycloalkyloxycarbonyl, substituted or unsubstituted cycloalkenyloxycarbonyl, substituted or unsubstituted aryloxycarbonyl, substituted or unsubstituted heteroaryloxycarbonyl, substituted or unsubstituted heterocyclyloxycarbonyl, substituted or unsubstituted carbamoyl, formyl, substituted or unsubstituted alkylcarbonyl, substituted or unsubstituted alkenylcarbonyl, substituted or unsubstituted cycloalkylcarbonyl, substituted or unsubstituted cycloalkenylcarbonyl, substituted or unsubstituted arylcarbonyl, substituted or unsubstituted heteroaryl carbonyl, substituted or unsubstituted heterocyclylcarbonyl, sulfino, sulfo, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted alkenyl sulfonyl, substituted or unsubstituted cycloalkylsulfonyl, substituted or unsubstituted cycloalkenylsulfonyl, substituted or unsubstituted arylsulfonyl, substituted or unsubstituted heteroarylsulfonyl, substituted or unsubstituted heterocyclylsulfonyl, substituted or unsubstituted sulfamoyl, or substituted or unsubstituted amino; m is an integer between 0 and 2; n is an integer between 0 and 3; R is halogen, oxo, cyano, nitro, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, or substituted or unsubstituted alkynyl; and p is an integer between 0 and 2.
  • Claim: 2. The compound of claim 1, wherein m is 1, or a pharmaceutically acceptable salt thereof.
  • Claim: 3. The compound of claim 1, wherein R1 is alkyl, or a pharmaceutically acceptable salt thereof.
  • Claim: 4. The compound of claim 1, wherein R3 is substituted or unsubstituted phenyl, substituted or unsubstituted pyridyl, substituted or unsubstituted pyrimidinyl, substituted or unsubstituted pyrazinyl, substituted or unsubstituted thiazolyl, substituted or unsubstituted oxazolyl, substituted or unsubstituted morpholinyl, substituted or unsubstituted morpholino, substituted or unsubstituted pyrrolidinyl, substituted or unsubstituted piperidyl, substituted or unsubstituted piperidino, substituted or unsubstituted benzodioxolyl, substituted or unsubstituted dihydrobenzoxazinyl, or substituted or unsubstituted indazolyl, or a pharmaceutically acceptable salt thereof.
  • Claim: 5. The compound of claim 1, wherein R4 is halogen, cyano, oxo, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkoxy, or substituted or unsubstituted aryloxy, or a pharmaceutically acceptable salt thereof.
  • Claim: 6. The compound of claim 1, wherein n is 1, or a pharmaceutically acceptable salt thereof.
  • Claim: 7. The compound of claim 1, wherein R1 is substituted or unsubstituted alkyl, R2 is hydrogen, Ring A is pyrrolopyridine, R3 is substituted or unsubstituted phenyl, substituted or unsubstituted pyridyl, substituted or unsubstituted pyrimidinyl, substituted or unsubstituted pyrazinyl, substituted or unsubstituted thiazolyl, substituted or unsubstituted oxazolyl, substituted or unsubstituted morpholinyl, substituted or unsubstituted pyrrolidinyl, or substituted or unsubstituted piperidyl, and R4 is halogen, cyano, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy or, substituted or unsubstituted aryloxy, or a pharmaceutically acceptable salt thereof.
  • Current U.S. Class: 544/127
  • Current International Class: 07

Klicken Sie ein Format an und speichern Sie dann die Daten oder geben Sie eine Empfänger-Adresse ein und lassen Sie sich per Email zusenden.

oder
oder

Wählen Sie das für Sie passende Zitationsformat und kopieren Sie es dann in die Zwischenablage, lassen es sich per Mail zusenden oder speichern es als PDF-Datei.

oder
oder

Bitte prüfen Sie, ob die Zitation formal korrekt ist, bevor Sie sie in einer Arbeit verwenden. Benutzen Sie gegebenenfalls den "Exportieren"-Dialog, wenn Sie ein Literaturverwaltungsprogramm verwenden und die Zitat-Angaben selbst formatieren wollen.

xs 0 - 576
sm 576 - 768
md 768 - 992
lg 992 - 1200
xl 1200 - 1366
xxl 1366 -